<DOC>
	<DOCNO>NCT01767129</DOCNO>
	<brief_summary>To evaluate efficacy , safety , tolerability AVP-923 capsule contain 45 mg dextromethorphan 10 mg quinidine ( AVP-923-45 ) compare placebo treatment levodopa-induced dyskinesia ( LID ) patient Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>Safety Efficacy AVP-923 Treatment Levodopa-induced Dyskinesia Parkinson 's Disease Patients</brief_title>
	<detailed_description>Proof-of-concept phase 2a , double-blind , randomize , placebo-controlled , crossover study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>Males females 30 80 year age , inclusive . Diagnosis idiopathic PD meeting United Kingdom Parkinson 's disease Society Brain Bank criterion . Levodopainduced dyskinesia present great 25 % day per MDSUPDRS . Dyskinesia least moderate severity per MDSUPDRS Amantadine Monoamine Oxidase ( MAO ) inhibitor must discontinue least three week prior randomization . Subjects currently receive antiparkinsonian medication , include Levodopa preparation eligible provide stable dose medication least 1 month prior randomization . Concomitant use antidepressant selective serotonin reuptake inhibitor allow , provide dose stable least 1 month prior randomization . Subject prior surgery PD except Deep Brain Stimulation ( Deep Brain Stimulation must perform within one year screening ) Hoehn Yahr score 5 `` '' . Subject Cognitive impairment and/or history psychiatric manifestation active hallucination . Subjects history complete heart block , QTc prolongation , torsades de pointes . Subjects family history congenital QT interval prolongation syndrome . Subjects history postural syncope , history unexplained syncope within last 12 month . Subjects history substance and/or alcohol abuse within past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>levodopa</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>parkinson 's disease</keyword>
	<keyword>AVP-923</keyword>
	<keyword>dextromethorphan</keyword>
	<keyword>quinidine</keyword>
</DOC>